How to Brief a Korean ODM: A Step-by-Step Template for Indie K-Beauty Founders (2026)
By the ALTA MEET editorial team | K-beauty ODM consulting
Reviewed for accuracy by ALTA MEET's formulation consulting team
A first-time founder's first brief usually arrives at the Korean ODM in one of two shapes. It is either three lines pasted from a Notion doc ("I want a niacinamide serum, premium feel, MOQ 1,000, ready by Q3"), or it is twelve pages of Pinterest mood boards with no spec, no MOQ, no claim language, and no markets named. Both shapes get the same response from a Seoul-side product manager: a polite reply, a long silence, and a sample that does not match the brand in the founder's head.
That silence is expensive. In 2026 the Korean ODM market is moving faster than ever, but the calendar from brief to first shipment still runs roughly six months end to end, with sample rounds eating four to six weeks each and stability testing locking in three to six months of accelerated data before mass production can start. Every brief revision after sample round one adds two to four weeks. A weak brief is not a slow start, it is a permanent timeline tax for the life of the product.
This guide is the template ALTAMEET sends to indie K-beauty founders before their first call with a Korean lab. It has nine sections, a reason each section exists, the specific data points to fill in, and the common ways founders get each section wrong. Use it to brief any Korean ODM, not only the ones we work with.
Why a Tight Brief Matters More in 2026
Three things changed in the last two years that raised the cost of a vague brief.
First, Korean ODMs are running fuller order books. Future Market Insights pegs the Korean cosmetics ODM market at roughly USD 705 million in 2025 with a 6.4 percent CAGR to USD 1.32 billion by 2035, and the well-known Kolmar and COSMAX queues have lengthened with the global indie boom. If your brief forces a Seoul product manager to ask three rounds of clarifying questions, your slot in the formulation queue slips. Founders with cleaner briefs ship sooner, not because the lab favors them, but because their files move through the queue without parking.
Second, MoCRA enforcement in the US went into steady-state in 2024-2025. Cosmetic facility registration and product listing under section 607 of the FD&C Act are now expected as standard practice. Brands with average gross annual US cosmetic sales under USD 1 million across the preceding three-year period qualify for the small business exemption from facility registration and product listing, but that exemption excludes products that contact the eye mucous membrane, are injected, are intended for internal use, or are intended to alter appearance for more than 24 hours when the consumer cannot remove them. Indie founders need to declare their regulatory plan in the brief because it changes which claims the formula can carry, which packaging is acceptable, and whether the ODM will require additional documentation.Third, ingredient cost volatility (peptides, exosomes, fermented actives) means the lab needs to know your cost ceiling early. We have seen finished formulas die at week eight because the founder did not declare a target price per unit at the brief stage and the lab built around a USD 6.20 cost-of-goods that the founder needed to be USD 3.80.
A tight brief solves all three.
Before You Write Anything: 4 Things to Lock Down First
These four decisions are upstream of the template. If they are not made, the brief cannot be written.
Manufacturing model. ODM (the lab develops a custom formula for your brand), OEM (you bring the formula, the lab manufactures it), or Private Label (you pick from existing lab formulas and put your label on them). Each requires a different brief depth. The rest of this template assumes ODM. If you are still deciding, see our Korean ODM vs OEM vs Private Label guide first.
Target launch markets. US only, US plus EU, US plus Korea domestic, global. This determines the regulatory section of the brief and changes which preservatives and UV filters are usable. A formula that ships to the EU cannot use methylisothiazolinone in leave-on products. A formula that ships to Korea cannot exceed the KFDA functional cosmetic threshold for whitening or anti-wrinkle without filing.
MOQ posture. Whether you are anchoring at 1,000 units (typical indie floor with flexible Korean ODMs in 2026) or 5,000 to 10,000 units (typical large-lab anchor). Mid-size and specialized indie-friendly ODMs have brought first-batch MOQs down to 1,000 to 2,000 units across serum, cream, and essence categories, and some have launched made-to-order pilot platforms with single-unit production. Large ODMs like COSMAX retain higher MOQs because their cost structure assumes scale. The brief should declare your MOQ position so the lab quotes against your reality, not theirs.
Cost target per unit at MOQ. A real number, in USD or KRW, ex-works Incheon. Not a margin, because the lab cannot work backwards from your retail price (it does not know your distributor cut). Derive the cost ceiling from your target retail price minus your channel margin minus your duties, freight, warehousing, and target gross margin. Write the number down before the call.
With those four locked, the nine-section brief is straightforward.
The 9-Section ODM Brief Template
Section 1: Brand and Positioning Context (half a page)
What goes here: brand name, founder name, brand age, headcount, current SKU count, brand archetype in one sentence, two or three competitor brands the lab can reference, and the channel the product launches into (DTC, Sephora, Olive Young, Amazon).
Why it matters: a Korean ODM has formulated for hundreds of brands. They translate "premium minimalist barrier-repair line, sold DTC to women 28-42 in coastal US cities" into texture, fragrance, packaging weight, and price tier faster than they translate "a clean Korean skincare brand for sensitive skin." Specificity here is the brief's force multiplier.Founder mistake: leaving this section empty because it feels like marketing fluff. It is not. It is the calibration data the lab uses to disambiguate every other section.
Section 2: Product Type and Sensory Target
Product format: serum, ampoule, essence, cream, gel-cream, sleeping mask, sheet mask, cleanser, toner, sunscreen, SPF moisturizer, etc.
Sensory target attributes, with at least two reference products the founder owns and likes: - Viscosity (thin water-like, light-serum, gel, thick cream) - Finish (dewy, satin, matte, plumping, blurring) - Absorption time (instant, 30-second sink-in, deliberate slow massage) - Fragrance level (unscented, neutral, light floral, herbal, citrus) - Color (clear, opaque white, beige, tinted)
Founder mistake: describing the sensory in adjectives only ("luxurious, plush, lightweight, rich, nourishing"). Adjectives compound, they do not converge. Two reference products beat ten adjectives every time.
Section 3: Hero Actives and Claims Boundary
List the actives you want as hero claims, in priority order, with target concentration ranges and the claim you intend to make on pack. For example: "Niacinamide 5 to 10 percent, claim 'visible pore appearance.' Bakuchiol 0.5 to 1 percent, claim 'visibly smoother texture.' Centella asiatica extract, claim 'soothing.'"
The concentration range matters because the lab will negotiate within it. The claim matters because the lab will tell you whether the concentration is sufficient to substantiate the claim under MoCRA (US), EU 1223/2009, or KFDA functional cosmetic rules. A 0.1 percent retinol cannot carry a "wrinkle reduction" claim in the EU, and a 0.3 percent niacinamide cannot carry a "pore" claim defensibly under MoCRA's substantiation standard.
Founder mistake: confusing what you want to put on pack with what you want the lab to put in the bottle. The brief is for the lab. The pack copy is downstream.
Section 4: Ingredient No-Go List
Specify ingredients to exclude, with reason where it helps the chemist. Three common indie no-go lists: - Allergen-aware: no fragrance, no essential oils, no methylisothiazolinone (MI), no methylchloroisothiazolinone (MCI) - Clean-positioning: no parabens, no PEGs, no silicones (specify which, since cyclic and linear silicones are different categories) - Brand-specific: no animal-derived ingredients (vegan), no synthetic colorants, no SLS/SLES
Founder mistake: copying a competitor's "free-from" list without understanding the trade-offs. Going phenoxyethanol-free in a water-based serum without backup preservation increases your microbiology risk and the lab will charge for the additional challenge testing under ISO 17516 or USP 51.
Section 5: Packaging Constraints
What goes here: target primary package (airless pump, dropper, tube, jar, sachet), volume (30 ml, 50 ml, 100 ml), material preferences (PCR percentage, glass, aluminum), and any deal-breakers (no plastic dropper bulbs, no airless because of breakage in transit).Why it matters: packaging changes the formula. An airless pump tolerates a wider viscosity range. A dropper requires a thinner viscosity. A jar exposes the product to air and fingers, which means more preservation and antioxidant load. A tube limits color (because light leaks through translucent tubes). The chemist needs to know the container before formulating because the formula has to survive it.
Founder mistake: treating packaging as a separate workstream that gets finalized after the formula. By then the chemist has formulated to a generic viscosity envelope and your dream package will need a reformulation.
Section 6: Regulatory Markets and Filing Plan
State explicitly: launch markets, year-one rollout markets, and who files what. For example: "US launch Q3 2026 (DTC and Amazon), EU launch Q1 2027 (Sephora EU). ALTAMEET handles US MoCRA registration and product listing as the responsible person. EU Responsible Person to be appointed by month 9. Korea domestic not in plan."
Why it matters: this section drives ingredient eligibility (UV filters and preservatives differ by market), required documentation (the EU requires a CPNP notification and a Cosmetic Product Safety Report under Annex I of EC 1223/2009), and the lab's stability protocol (markets with strict regulatory frameworks expect full ICH Q1A(R2) accelerated data, while DTC-only launches sometimes proceed on 3-month accelerated alone).
Founder mistake: saying "we will figure out compliance after we have the formula." The compliance frame must be set at brief stage. Our FDA Korean skincare import guide covers the MoCRA setup in detail.
Section 7: MOQ, Cost Target, and Tier Pricing
State your anchor MOQ (e.g., 1,000 units for first batch), your target cost ex-works at that MOQ in USD or KRW, and a re-order tier (e.g., "at 5,000 units, expect a 12 to 18 percent cost reduction; at 10,000 units, expect 20 to 25 percent"). Indie-friendly Korean ODMs typically quote against 1,000 to 2,000 unit first batches, and large ODMs retain 5,000+ unit floors.
Why it matters: the lab will design the formula and source ingredients to the cost ceiling. If you ask for "best price possible" without a number, the lab will benchmark you against the cost-of-goods of a USD 38 retail serum, which may be far from your USD 22 retail position.
Founder mistake: under-declaring the MOQ to "see what is possible." The lab gives a worse quote on a 500-unit anchor than on a 1,500-unit anchor because the per-unit cost of formulation development, stability testing, and QC is fixed and the unit count is what amortizes it.
Section 8: Stability and QC Expectations
Specify the stability window you need: 24-month shelf life is standard, 36-month is achievable for stable formulas, 18-month is acceptable for some categories (sheet masks). The ICH Q1A(R2) baseline for cosmetics adapted from pharmaceuticals expects 6 months of accelerated stability at 40°C ± 2°C and 75% ± 5% relative humidity, which predicts approximately 24 months at controlled room temperature. Long-term real-time stability runs 12 months at 25°C ± 2°C / 60% ± 5% RH and continues to support the claimed shelf life.State the QC checks you require beyond the lab's baseline: microbiology (USP 51 challenge, USP 61 microbial enumeration, USP 62 absence of objectionable organisms), heavy metals panel for international shipping, allergen panel for EU compliance, color stability, viscosity stability, and pH drift tolerance.
Founder mistake: skipping this section because "the lab handles it." The lab handles its baseline. Your brand's risk tolerance for color drift after 18 months at the back of a Target shelf is your decision, not the chemist's.
Section 9: Timeline and Decision Gates
Set the calendar with named gates: - Brief signoff and quote: week 0 to 2 - Sample round 1: weeks 4 to 6 (lab develops 2 to 3 candidate formulas) - Sample round 2: weeks 8 to 10 (founder selects direction, lab refines) - Sample round 3 (if needed): weeks 12 to 14 - Pilot batch and stability start: week 14 to 16 - Accelerated stability data review: week 28 to 30 - Mass production start: week 30 to 32 - First shipment ex-works Incheon: week 36 to 40
Korean ODM lead times for sampling and first production runs are typically 30 to 50 percent faster than Southeast Asian or Chinese equivalents, which is the real reason indie brands queue for Seoul slots. Our Korean ODM launch timeline guide walks through the gates in more depth.
Founder mistake: leaving the gates unstated. Without named gates, every round drifts. Three-week reviews become five-week reviews. The lab is not going to chase you, the lab has nine other clients in the queue.
I'm Liz, I run altameet from Manhattan, NYC. The two-page version of this template lives in our intake doc, and most founders who fill it out end up with a sample they want to keep in round one or round two, not round three. If you want a quick gut-check on whether your brief is ready to send to a Seoul ODM, I'll give you 15 minutes free. Email me at liz@altameet.com or our team at partnerships@altameet.com.
Common Brief Mistakes That Add 4 to 8 Weeks
Across the briefs we have reviewed for indie K-beauty founders since 2024, six mistakes repeat.
1. The "vibe brief." Five paragraphs of brand voice and zero ingredient or sensory spec. The lab cannot start. Two weeks lost waiting for a clarification round.
2. The "everything brief." Twelve hero actives, eight no-go lists, four packaging options, three markets. The lab quotes against the easiest interpretation, which will not match the founder's intent. Add two rounds and four weeks.
3. The "moving target brief." The brief changes between round 1 and round 2 because the founder did more research mid-cycle. Each change resets the chemist's clock. Two to three weeks per change.4. The "claim-first brief." Founder writes the pack copy first, then asks the lab to substantiate it. Sometimes the claim requires a concentration that breaks the texture target or busts the cost ceiling. Reverse the order: brief the formula intent, then write claims against what the lab can substantiate.
5. The "MOQ-evasive brief." Founder hides the MOQ hoping the lab will surprise them with a lower one. The lab does not surprise. Declare the MOQ.
6. The "regulatory-deferred brief." Founder says "we will deal with compliance later." Then a UV filter or preservative is wrong for the target market and the formula needs surgery. Set the regulatory frame at brief stage.
How the Brief Evolves Across Sample Rounds
The brief is not a static document. It is a versioned spec that gets tighter each round.
Round 1 (weeks 4 to 6). The lab returns 2 to 3 candidate formulas. The brief gets annotated with what worked and what did not against each section. Sensory target tightens. No-go list may add 1 to 2 ingredients the founder reacted to. Cost target gets a reality check against the lab's first quote.
Round 2 (weeks 8 to 10). The lab refines the selected direction. The brief now reads as a near-final spec sheet. Stability protocol locks. Packaging selection locks. Claims wording locks because the substantiation data dictates what the pack can say.
Round 3 (weeks 12 to 14, optional). Polish-only round. Color tweak, fragrance level tweak, viscosity tweak. If you are still in major structural revision at round 3, the brief was wrong at round 0 and you should pause to rewrite it rather than fight through three more rounds.
Pilot batch and stability start at week 14 to 16 once the brief is locked. Accelerated stability runs 12 weeks (3 months at 40°C / 75% RH per the adapted ICH Q1A(R2) protocol), real-time runs 12 months in parallel. Mass production starts once accelerated data clears, typically around week 30.
Adapting the Template for Different Product Categories
The nine sections do not change. The depth in each one does.
Serum or ampoule. Section 2 (sensory) and Section 3 (actives) get the deepest treatment. Section 5 usually defaults to dropper or airless pump in 30 to 50 ml.
Cream or moisturizer. Section 5 (packaging) becomes critical because jars, tubes, and airless pumps all behave differently with cream formulas. Section 8 emphasizes color and texture stability over 24 months.
Sheet mask. Section 5 shifts to fabric choice (microfiber, hydrogel, bio-cellulose), Section 8 shortens to an 18-month shelf life, and Section 7 (MOQ) often drops to a 5,000 to 10,000 unit standard floor.
Sunscreen or SPF moisturizer. Section 6 (regulatory) becomes the biggest section. In the US, sunscreens are OTC drugs under FDA monograph rules, not cosmetics under MoCRA. UV filter selection differs by market because the US monograph approves fewer filters than the EU or Korea.Cleanser. Section 3 simplifies because surfactant chemistry dominates. Section 7 sharpens because cleansers price at a lower retail tier.
Key Takeaways
The brief is a 5-page document covering 9 sections, not a 1-line message and not a 12-page mood board.
Lock four decisions before writing: manufacturing model, target markets, MOQ anchor, cost ceiling.
Each section has a reason. Skip a section and the lab fills it in with their default, which is usually wrong for an indie brand.
Hero actives and claims are negotiated together, not separately, because the concentration determines what claim is defensible under MoCRA, EU 1223/2009, or KFDA.
State the MOQ. Hiding the MOQ produces a worse quote, not a better one.
Package the brief with a calendar of named gates so the file moves through the lab queue without parking.
Sample round 3 is for polish. If you are still in structural revision at round 3, rewrite the brief.
FAQ
Q: How long should a first ODM brief be? A: Four to six pages for a single-SKU brief, eight to ten pages for a three-SKU collection. Less than three pages is usually too thin to act on. More than ten pages without a one-page executive summary is too dense for a chemist to scan quickly.
Q: Should I share my retail price in the brief? A: No. Share the cost ceiling ex-works Incheon at your MOQ. Retail price introduces channel margin assumptions the lab cannot estimate and does not need.
Q: What if I do not know my exact MOQ yet? A: Anchor at 1,000 units for indie K-beauty in 2026 with a flexible Korean ODM, and ask the lab to quote a price tier at 1,000 / 3,000 / 5,000. That gives you decision data without locking you in.
Q: How many hero actives should I name? A: One primary, one secondary, one supporting. Three is the working ceiling for a single SKU because each active adds formulation complexity, cost, and claim-substantiation load. Five actives in one SKU is a marketing brief, not a product brief.
Q: Do I need to specify the preservation system? A: Not the exact preservatives, but the constraints. Specify what the formula cannot contain (parabens, MI, MCI, formaldehyde releasers if any) and the target microbiology spec (ISO 17516 baseline of 1,000 CFU/g for leave-on products is standard for general cosmetics; 100 CFU/g for eye, pediatric, and mucosal products). The lab will select the specific preservative system within those constraints.
Q: Should the brief specify the supplier of hero actives? A: Usually no. The lab picks the supplier because they manage IQOA (incoming quality of asset) on their own approved vendor list. If you have a strategic ingredient story (a specific fermented active from a named supplier, for example), specify it in Section 3 with the supplier name and ask the lab to qualify them into the vendor list. Expect a 3 to 5 week vendor qualification step if so.Q: How is the brief used after mass production? A: It becomes the master spec sheet for re-orders, line extensions (a 30 ml retail size derived from a 50 ml pilot, for example), and regulatory filings. Keep it versioned in your brand's archive. When you go for an EU CPNP filing or a Sephora vendor onboarding, the brief is the document the responsible person and the buyer will both want to see.
References
US Food and Drug Administration. Registration and Listing of Cosmetic Product Facilities and Products. Modernization of Cosmetics Regulation Act of 2022 (MoCRA), section 607 of the Federal Food, Drug, and Cosmetic Act.
US FDA. Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products. Final Guidance, December 2024.
International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Adopted as cosmetic stability baseline by most Korean ODMs.
ISO 22716:2007. Cosmetics, Good Manufacturing Practices (GMP).
ISO 17516:2014. Cosmetics, Microbiology, Microbiological limits.
ISO 11930:2019. Cosmetics, Microbiology, Evaluation of the antimicrobial protection of a cosmetic product.
USP 51 Antimicrobial Effectiveness Testing; USP 61 Microbial Enumeration Tests; USP 62 Tests for Specified Microorganisms.
European Commission. Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products. Annex I, Cosmetic Product Safety Report.
Korea Ministry of Food and Drug Safety (KFDA). Cosmetics Act and Functional Cosmetics Notification.
Future Market Insights (2025). Korea Cosmetics ODM Market Size and Industry Trends 2025 to 2035.
ALTAMEET is a New York based K-beauty manufacturing partner. We help indie and growing US beauty brands run Korean ODM development with founder-led oversight from brief through first shipment. If you want a 15-minute brief review before sending to a Seoul lab, reach the team at partnerships@altameet.com.
